266 related articles for article (PubMed ID: 20367530)
1. Nanostructured hyaluronic acid-based materials for active delivery to cancer.
Ossipov DA
Expert Opin Drug Deliv; 2010 Jun; 7(6):681-703. PubMed ID: 20367530
[TBL] [Abstract][Full Text] [Related]
2. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives.
Oh EJ; Park K; Kim KS; Kim J; Yang JA; Kong JH; Lee MY; Hoffman AS; Hahn SK
J Control Release; 2010 Jan; 141(1):2-12. PubMed ID: 19758573
[TBL] [Abstract][Full Text] [Related]
3. Cationic nanoparticles for cancer therapy.
Bilensoy E
Expert Opin Drug Deliv; 2010 Jul; 7(7):795-809. PubMed ID: 20446858
[TBL] [Abstract][Full Text] [Related]
4. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel.
Cho HJ; Yoon HY; Koo H; Ko SH; Shim JS; Lee JH; Kim K; Kwon IC; Kim DD
Biomaterials; 2011 Oct; 32(29):7181-90. PubMed ID: 21733572
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers.
He M; Zhao Z; Yin L; Tang C; Yin C
Int J Pharm; 2009 May; 373(1-2):165-73. PubMed ID: 19429302
[TBL] [Abstract][Full Text] [Related]
6. An insight on hyaluronic acid in drug targeting and drug delivery.
Yadav AK; Mishra P; Agrawal GP
J Drug Target; 2008 Feb; 16(2):91-107. PubMed ID: 18274931
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.
Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP
J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659
[TBL] [Abstract][Full Text] [Related]
8. Cancer cell specific targeting of nanogels from acetylated hyaluronic acid with low molecular weight.
Park W; Kim KS; Bae BC; Kim YH; Na K
Eur J Pharm Sci; 2010 Jul; 40(4):367-75. PubMed ID: 20417709
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid for anticancer drug and nucleic acid delivery.
Dosio F; Arpicco S; Stella B; Fattal E
Adv Drug Deliv Rev; 2016 Feb; 97():204-36. PubMed ID: 26592477
[TBL] [Abstract][Full Text] [Related]
10. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies.
Negi LM; Talegaonkar S; Jaggi M; Verma AK; Verma R; Dobhal S; Kumar V
Colloids Surf B Biointerfaces; 2014 Nov; 123():610-5. PubMed ID: 25454755
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in hyaluronic acid-based nanomedicine for targeted cancer treatment.
Rao NV; Yoon HY; Han HS; Ko H; Son S; Lee M; Lee H; Jo DG; Kang YM; Park JH
Expert Opin Drug Deliv; 2016; 13(2):239-52. PubMed ID: 26653872
[TBL] [Abstract][Full Text] [Related]
12. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach.
Varghese OP; Sun W; Hilborn J; Ossipov DA
J Am Chem Soc; 2009 Jul; 131(25):8781-3. PubMed ID: 19499915
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
14. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery.
Jiang T; Zhang Z; Zhang Y; Lv H; Zhou J; Li C; Hou L; Zhang Q
Biomaterials; 2012 Dec; 33(36):9246-58. PubMed ID: 23031530
[TBL] [Abstract][Full Text] [Related]
15. Drug-binding hydrogels of hyaluronic acid functionalized with beta-cyclodextrin.
Zawko SA; Truong Q; Schmidt CE
J Biomed Mater Res A; 2008 Dec; 87(4):1044-52. PubMed ID: 18257063
[TBL] [Abstract][Full Text] [Related]
16. [Hyaluronic acid-based carriers for tumor targeted delivery system].
Qiu LP; Long MM; Chen DW
Yao Xue Xue Bao; 2013 Sep; 48(9):1376-82. PubMed ID: 24358769
[TBL] [Abstract][Full Text] [Related]
17. Self-assembled hyaluronic acid nanoparticles for active tumor targeting.
Choi KY; Chung H; Min KH; Yoon HY; Kim K; Park JH; Kwon IC; Jeong SY
Biomaterials; 2010 Jan; 31(1):106-14. PubMed ID: 19783037
[TBL] [Abstract][Full Text] [Related]
18. Liposomal cancer therapy: exploiting tumor characteristics.
Kaasgaard T; Andresen TL
Expert Opin Drug Deliv; 2010 Feb; 7(2):225-43. PubMed ID: 20095944
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronate derivatives in drug delivery.
Vercruysse KP; Prestwich GD
Crit Rev Ther Drug Carrier Syst; 1998; 15(5):513-55. PubMed ID: 9822869
[TBL] [Abstract][Full Text] [Related]
20. Passive and active drug targeting: drug delivery to tumors as an example.
Torchilin VP
Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
